ArticleEye (London, England)2026
Neovascular glaucoma incidence and visual outcomes in treated proliferative diabetic retinopathy with anterior segment neovascularisation.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Circumferential quantitative analysis of iris angiography reveals progressive pupillary-margin leakage across stages of diabetic retinopathy.BMC ophthalmology · 2026Observational
- Comment on: 'Neovascular glaucoma incidence and visual outcomes in treated proliferative diabetic retinopathy with anterior segment neovascularisation'.Eye (London, England) · 2026Article
- Pathogenesis of Neovascular Glaucoma in Diabetic Retinopathy: A Review.Journal of ophthalmology · 2026Review
- Systemic Inflammatory and Microcirculatory Determinants of Long-Term Outcomes in Neovascular Glaucoma: A Multicenter Cohort Study.Romanian journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnterior segment neovascularisation (ASNV), including neovascularisation of the iris (NVI) and angle (NVA), is a known complication of proliferative diabetic retinopathy (PDR), but outcomes specific to this group remain poorly characterised. We aimed to evaluate visual and intraocular pressure (IOP) outcomes in patients with ASNV secondary to PDR, stratified by anatomical stage, and to assess the incidence of neovascular glaucoma (NVG).
methodsThis retrospective cohort study included 116 eyes from 72 patients with treated PDR and ASNV treated between 1/1/2017 and 31/12/2023. Eyes were stratified into three groups: NVI only; NVI and/or NVA without peripheral anterior synechiae (PAS); and eyes with PAS. Data on visual acuity (VA), IOP, treatment, and disease progression were collected. Median follow-up was 42.5 months.
resultsVisual outcomes and IOP control were significantly worse in eyes with PAS. Final median logMAR VA was 0.36 in the NVI group, 0.44 in the NVI/NVA group, and 2.30 in the PAS group (p = 0.009). Vision loss ≥3 lines occurred in 34%, 31%, and 71% of eyes, respectively (p = 0.010). Final VA ≥ 1.0 logMAR was recorded in 71% of PAS eyes, compared to 18.2% in the other groups (p < 0.001). NVG developed in 9/116 eyes (7.8%) overall, exclusively in the PAS subgroup (9/17 eyes, 53%). Glaucoma surgery was required in 41% of eyes with PAS.
conclusionsIn treated PDR, NVI or NVA alone was generally compatible with visual stability, whereas PAS were associated with high NVG incidence and poor vision. Early gonioscopic detection and aggressive treatment are critical to prevent synechial angle closure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.